Analysis of diroximel fumarate data for patients with relapsing forms of multiple sclerosis using related adverse...

Area of Science:

• Pharmacovigilance
• Neurology
• Oncology

Background:

• Diroximel fumarate (DRF) is an oral fumarate treatment for relapsing forms of multiple sclerosis (RMS).
• Adverse events (AEs) associated with DRF require ongoing comprehensive analysis.
• The FDA Adverse Event Reporting System (FAERS) database is a key resource for pharmacovigilance.

Purpose of the Study:

• To comprehensively analyze adverse events (AEs) linked to diroximel fumarate (DRF) in relapsing multiple sclerosis (RMS) patients.
• To identify potential new safety signals not previously documented for DRF.
• To utilize robust statistical methods for AE signal detection in real-world data.

Main Methods:

• Data extraction from the FDA Adverse Event Reporting System (FAERS) database (2019-2024).
• Application of multiple statistical algorithms including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS) for signal detection.
• Analysis of 7,868 AE reports associated with DRF, encompassing 120 preferred terms across 27 system organ classes.

Main Results:

• Identification of several clinically significant potential AEs associated with DRF.
• Notable findings include decreased immune responsiveness (ROR 4.45), female breast cancer (ROR 4.07), and transient blindness (ROR 7.27).
• These signals suggest potential safety concerns beyond currently listed DRF contraindications.

Conclusions:

• The study identified potentially significant AEs for diroximel fumarate (DRF) not detailed in current product information.
• These findings highlight the importance of continuous pharmacovigilance for oral fumarates in RMS treatment.
• Further epidemiological studies are recommended to validate the identified safety signals and inform clinical practice.